Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Initial Treatment	STARTED	Fulvestrant and Dasatinib	50
Initial Treatment	STARTED	Fulvestrant	49
Initial Treatment	COMPLETED	Fulvestrant and Dasatinib	0
Initial Treatment	COMPLETED	Fulvestrant	0
Initial Treatment	NOT COMPLETED	Fulvestrant and Dasatinib	50
Initial Treatment	NOT COMPLETED	Fulvestrant	49
Progression and Cross-over	STARTED	Fulvestrant and Dasatinib	0
Progression and Cross-over	STARTED	Fulvestrant	21
Progression and Cross-over	COMPLETED	Fulvestrant and Dasatinib	0
Progression and Cross-over	COMPLETED	Fulvestrant	0
Progression and Cross-over	NOT COMPLETED	Fulvestrant and Dasatinib	0
Progression and Cross-over	NOT COMPLETED	Fulvestrant	21

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00754325/flow